{
  "ticker": "JNJ",
  "target_date": "2025-06-04",
  "actual_date": "2025-06-04",
  "collected_at": "2025-12-08T11:50:55.884002",
  "price": {
    "open": 152.83,
    "high": 152.83,
    "low": 151.06,
    "close": 151.14390563964844,
    "volume": 6983900,
    "change_1d_pct": -0.78,
    "change_7d_pct": 1.04,
    "change_30d_pct": -2.04
  },
  "technicals": {
    "rsi_14": 75.03,
    "sma_20": 150.07,
    "sma_50": 151.49,
    "macd": 0.112,
    "macd_signal": -0.39,
    "macd_histogram": 0.502,
    "bb_upper": 155.52,
    "bb_lower": 144.62,
    "price_vs_sma20_pct": 0.72,
    "price_vs_sma50_pct": -0.23,
    "volume_ratio": 0.83
  },
  "fundamentals": {
    "market_cap": 489219391488,
    "pe_ratio": 19.599903,
    "forward_pe": 19.15613,
    "price_to_book": 6.16308,
    "price_to_sales": 5.309004,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.29,
    "pct_from_52w_low": 44.34
  },
  "macro": {
    "spy": {
      "price": 592.53,
      "change_1d_pct": -0.03,
      "change_7d_pct": 0.81
    },
    "vix": {
      "level": 17.61,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.36
    },
    "dollar_index": {
      "level": 98.79
    },
    "gold": {
      "price": 3373.5
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer",
      "source": "Yahoo",
      "datetime": 1749053820,
      "summary": "Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.",
      "url": "https://finnhub.io/api/news?id=5fd8f76625cad9aa6e2e500f3a24cdf5b44cc920bc28ca17b28386c061f2e978"
    },
    {
      "headline": "J&J may take a softer tariff hit after US-China pause, CFO says",
      "source": "Yahoo",
      "datetime": 1749027600,
      "summary": "Joseph Wolk told an investor conference that the company\u2019s tariff estimate is a \u201cmoving target\u201d as trade talks continue with China and Europe and Section 232 investigations are ongoing.",
      "url": "https://finnhub.io/api/news?id=55813b2307364b78dcf347abb7c8f140ea1f1f648d96110febf47f3c67f9c8ed"
    },
    {
      "headline": "Johnson & Johnson MedTech introduces automated system for surgical efficiency",
      "source": "Yahoo",
      "datetime": 1749026890,
      "summary": "The system features increased reverse energy to aid in broach removal and push-to-lock adaptors for secure connections.",
      "url": "https://finnhub.io/api/news?id=b8430e09a1eb6e1257aa247e2fa9ed3c469f89263feb2b4a577672ba855208f5"
    },
    {
      "headline": "Johnson & Johnson Launches KINCISE 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures",
      "source": "Finnhub",
      "datetime": 1749019167,
      "summary": "Palm Beach Gardens - Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, announced the launch of the KINCISE 2 Surgical Automated System, a next-generation automated...",
      "url": "https://finnhub.io/api/news?id=b2918beacad26a829a50e6d1149f58a6b0582457c3206017491877d4e9998510"
    },
    {
      "headline": "J&J: promising results in multiple myeloma",
      "source": "Finnhub",
      "datetime": 1749018850,
      "summary": "Johnson & Johnson announces positive initial Phase 1 results for JNJ-79635322 , an investigational trispecific antibody for patients with relapsed or refractory multiple myeloma. In the 36 patients...",
      "url": "https://finnhub.io/api/news?id=0f3ce02516bc373477882687860ce9c071e4eab0d242378a8d1974d9597fa990"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}